Good day, ladies and gentlemen. Welcome, and thank you for joining Eurofins' first quarter 2026 trading update conference call. Please note that this call is being recorded and will later be available for replay on Eurofins' investor relations website. Throughout today's presentation, all participants will be in a listen-only mode. The presentation will be followed by a question and answer session. If you would like to ask a question, you may press star followed by one on your touch tone telephone to register for questions. For operator assistance, please press the star key followed by zero. During this call, Eurofins' management may make forward-looking statements, including but not limited to, statements with respect to outlook and the related assumptions. Management will also discuss alternative performance measures such as organic growth and EBITDA, which are defined in the footnotes of our press release. Actual results may differ materially from objectives discussed. Risks and uncertainties that may affect Eurofins' future results include, but are not limited to, those described in the risk factors section of the most recent Eurofins annual and half year reports. Please also read the disclaimer on page two of this presentation, subject to which this call and the Q&A session are made. I would now like to turn the conference over to Dr. Gilles Martin, Eurofins' Chief Executive Officer. Please go ahead. Hello, everybody, and welcome to our quarterly call. It's a limited comment that I will make today. In Q1, it was a continuation of last year. We've had a softer revenue growth with a big impact on weather. Those who live in North America, in the Midwest or the East Coast, and even in the South, will remember that January and February were particularly harsh with storms and unprecedented weather. In Northern Europe, we had a similar situation. I read somewhere that Finland had the worst winter in 40 years this year. You can all do your research about that. How does that impact us? Well, when there is snow and storm and we don't get samples coming into our labs, we can't test. When in environment, when people cannot go and sample outside because it's too cold, everything is frozen, we don't test. People don't go to the doctor to get tested. They don't go to the hospital to get their procedure. This has all an impact. Every winter, of course, we have an impact. It's a matter of magnitude, and normally we catch up during the year. It just happens that this year was extreme here. I've had question of how do we quantify that. Well, Q1 at 62.5 days. If you have to shut down three days, not even a full week, you're losing 5% of your revenues for the month if people can't come to work or you don't get samples. So that's relatively easy to see that the impact can be significant. Of course, we get the question, can we catch up? Normally, we catch up. Just happens that this year, the catch up might take probably longer than just one quarter because we had a very strong. However, also March had one more day, but even with that effect, March was back to our mid-single digit target. However, it was not enough to compensate for what happened in the earlier part of the quarter. We do think that much of that will come back at some point during the year, maybe not fully. Overall, we are sticking with our objective of mid-single digit organic growth for the full year. Overall, our business is doing well. We have a slideshow if you want. I'm on page three, but I will not read everything from the slideshow. You're welcome to go back and read it yourself or ask further questions in the call later. Overall, our business is doing well. Our BioPharma Product Testing is doing well. We continue to build our hub-and-spoke network, the completion of which is making further progress. We will be done by the end of 2027, as we believe. We start to see the impact of that, because even with fairly soft growth in Q1, losing some volume due to weather, for example, we still continued to improve significantly our profitability. We are very confident on our objectives to achieve the profitability and cash flow growth that we have set for this year and next year. The core BioPharma Product Testing, as I said, is doing well, is mid-single digit. We still have a softness in the ancillary biopharma. Discovery is also still a little bit soft, the very early phase of biopharma. Genomics, forensics, agroscience, unfortunately, are dragging the growth. We will hit bottom on those activities. We've done a lot of rationalization. We also continue to rationalize the contracts that we acquired from SYNLAB in Spain. They had a lot of loss-making contracts that we are exiting. We're exiting some of the distributorship we had in clinical diagnostics in Italy, which also has an impact on the growth. How long will that go? Well, probably SYNLAB, we should be done this year with the cleanup and probably also Italy. We've exited completely one activity in the Netherlands in clinical diagnostics because we didn't see potential upside. We are really making the company very efficient, highly digital, and we're quite positive for the outlook. On page four, we give a breakdown. Of course, we have an FX impact. It's very difficult to predict what the further FX impact will be going forward. If some of you know, please tell me how the currencies will evolve. On page five, we give a bit more color on the various components of the growth in the different activities, life, biopharma, and diagnostics. Biopharma includes ancillary activities like agroscience, genomics, forensics, which are really diluting the growth of our core business. Our CDMO is also quite lumpy. We actually got an award as one of the best or the best mid-scale CDMO recently, yesterday or the day before. We have a good product, but it's fairly lumpy. When you're small, you get a big contract, and that has an impact. Overall, we like that activity, the profitability of which, especially on our large campus in Toronto, is doing very well. On page six, we talk about acquisitions, where we continue our acquisition plan. We do think we can achieve the EUR 250 million additional revenue in 2026, a smaller bolt-on acquisition at acceptable multiples. On page seven, maybe I can give a bit more color on the divestment of our electrical and electronic testing business. We had talked about the possibility of such things happening. We like consumer product testing. This is definitely not an exit of consumer product testing. We believe consumer product testing has a strong impact on health. If you take cosmetics, those are things that we put on our skin and definitely impact our health, and they fit very well in Testing for Life. If you get things from your shoes and they leak chemicals, this has also an impact. You might have seen recently, the Texas state suing Lululemon for PFAS contained in clothing. Indeed, clothing may contain chemicals, so the level of health impact is there potentially. We do like consumer products. We think they fit very well. Electrical and electronic was a little bit different. It's more like type certification of products. It's not checking every single batch or every single product. We thought the fit with our Testing for Life objectives was not perfect. Also, we were relatively small in that area. We are in many countries. It was pretty obvious that it is a better fit with the buyer, UL, which already has a global network in this activity. We would have had to develop all the digital backbone specific to that activity. We all know it's essential for long-term efficiency and leadership, and that was a bit too small to do the spend that we thought was required to make that platform the best in its activity in digital. As you can see the terms of that, I think it's a good highlight of what we have in the portfolio of Eurofins. It wasn't by far our strongest business. It was a business where actually we hadn't started the digital journey. I think the acquirer has the right digital tool, and so they can deploy that. For them, it's very good. For us, it would have cost a lot of capital to put the digital backbone in place, the hub and spoke and so on. We didn't have the scale to build proper hub and spoke. We had good accreditation. It is a nice global platform in that area. It's definitely, if I compare it to the rest of Eurofins, not a crown jewel by far. It shows in terms of valuation, what is contained in Eurofins' businesses. I think the remaining businesses are definitely, for us, from our perspective, more potential. On the page eight, we are just repeating our objectives. Although the Q1 was a bit soft, we think we will achieve our goals for this year. We have already achieved significant continued profitability growth. On the M&A, we are on track. On our digitalization programs and building the hub-and-spoke network, we are on track. That's it for my short introduction. We can go to Q&A, and I can answer some specific questions. Thank you. Ladies and gentlemen, at this time, we will begin the question-and-answer session. Anyone who wishes to ask a question may press star followed by one on their touch tone telephone. If you wish to remove yourself from the question queue, you may press star followed by two. If you're using speaker equipment today, please lift the handset before making your selections. Anyone who has a question may press star followed by one at this time. One moment, please. Thank you. Our first question today will be coming from Remi Grenu with Morgan Stanley. Your line is live. Good afternoon, and thanks for taking my question. I've got two on my side. The first one would be on the biopharma division performance, which seems to have slightly weakened sequentially versus Q4. I just want to try to understand which subsegments within that division have seen the most organic growth pullback versus what you had in Q4, and if there is any explanation for the slight weakness there. As part of that question, are you still confident in a potential recovery in the second half of the year? I know, discussing some of the contracts within Central Lab, for example, and I think you're making some more positive comments on the pipeline as well and the contract wins. That would be the first question, biopharma. The second one. On the divestment, are there any other parts of the business you think could be potential candidates? Specifically on the divestment you've made, what would be the preferred use of the cash proceeds that you've received for the sale? Thank you. No, I don't think BioPharma is weakened. We have a number of ancillary activity in BioPharma, and they have not performed as they will and they should. That's the main factor. We also had some weather impact on BioPharma. It's not like any business in North America was fully immune to the situation. As I mentioned, our CDMO, and especially in Europe, had a trough with a lot of contracts finishing with significant clients, so that had an impact. Our bioanalysis business is still soft, so those new contracts in Central Lab and so on haven't started, so we still have a negative development there. I think that's the main thing. The trend is really as we anticipated. We do expect recovery. As usual, the timing of recovery is always difficult to determine, especially for the clinical areas where you have large contracts which are fairly lumpy and you never know exactly when they will start. Our clients, one of our largest clients recently reconfirmed they really want to go ahead. Timing of that, we will see. On divestment, we have nothing specific on the agenda. We are doing a bit of, as I mentioned, a portfolio cleanup on smaller things. It can be contract or smaller activities. We exited clinical diagnostics in Brazil, for example. That was last year. We have a few smaller things that are ongoing anyway to really clean up our network. We have some inbounds, obviously, on a number of areas. We don't need to do any additional divestments. We could potentially, at some point. We do active portfolio management, and we have to be the best owner of all assets. We also look at some other M&A assets that could be interesting. It's not that we want to shrink overall. We want to grow, but in areas where we are global market leaders and we see some upside. There's nothing imminent on the horizon. Of course, everything is possible. Some things are possible. The use of proceeds, you asked, well, we disclosed it in the press release. The general business, first of all, it will reduce our overall leverage, and then, depending on opportunities on M&A, we might use some of it for that. If not, we might use it for share buyback, but that depends, of course, on our share price. We have a number of options to allocate capital, and we are driven by return. We allocate capital where we think it provides a return significantly above our hurdle rates, and that's how we will manage. Short-term, it's mostly debt reduction. Okay, thank you. If I just may ask a follow-up on that. Just taking a step back and given the recent Intertek announcement, I'm interested in hearing what you think around sum-of-the-parts valuation consideration on the business and whether you would be open to the idea of a broader strategic review on how to potentially crystallize any potential value, if there is value, into a sum-of-the-parts consideration. No value is always there for the long-term owner. What the market says today doesn't define the value of the asset if someone wants to own that asset long term. So no, there is nothing on the agenda like this. However, on the sum of the parts, I've made no secret of the fact that I believe that our share price is, at the moment, currently massively undervalued compared to the sum of the parts and this small divestment for 2.5% of Eurofins, it shows clearly. If you take, for example, medical sales revenues, a massive gap exists. As I said, I don't think that part was any more profitable, any more faster growing for the recent past or had any more general attributes that made it more worthwhile than any other assets that we own. The market is always right at the moment, at any moment. In the long term, I think the value always comes out. Understood. Thank you very much. Thank you. Once again, ladies and gentlemen, if you do have any questions, please press star one on your telephone keypad. Our next question is coming from Neil Tyler with Rothschild & Co, Edinburgh. Your line is live. Yeah, thank you. Good afternoon, Gilles. Two questions, please. Firstly, around your investment program, and you talk about investing in the digital backbone, which has been taking place for a little while now. Can you talk about how perhaps those investments may have had to have changed over the last couple of years against the background of AI and large language model development, and how that's allowed you to either accelerate or perhaps have had to increase investments and how you've thought about the sort of integrated digital infrastructure across the business? That's the first question. And the second one, much more specifically, you mentioned some reimbursement issues in the diagnostics business in North America, having held back revenue growth in this period. Can you talk a bit about what that was, and what the sort of incremental risk of the same thing repeating is again, because it was my perception at least that the majority of the North American diagnostics business was less exposed to those sorts of issues, which have obviously been a feature in Europe? Thank you. Thank you very much. Our digitalization program hasn't changed much with AI. We have deployed coding tools, obviously AI coding tools. The impact on the speed of development so far is fairly modest, unfortunately. Of course, we're reading about many others. While in the future, a lot of people hope that development will come much faster with AI, this impact is relatively slow. Does it speed up our development by 10%, 15% now? Maybe. That's about all the quality of code is improving, obviously. All the coders have to learn to use those tools. Now we go to agentic AI, and what happens? There was an interesting article in Bloomberg yesterday about actually what happens inside Google for their own coding needs. You're talking, there are a number of coding tools that accelerate and facilitate coding. Some are for a few quarters better than others, but you end up having only a small part of your developers who are able to use them to the full capability of the tool. It's learning, so it's an adaptation. Maybe on the long term, the speed, acceleration of development that will be provided by that will be more significant. In the end, what matters, you have to define what you want to do. In any case, that is the most difficult thing, because you have to define exactly what processes you want to standardize around, and that is real engineering. I'm not sure AI does it really for you at the moment. I do think it will certainly help us to get our program delivered on time. As times go, we can improve our capabilities and our tools. AI is not a game changer, unfortunately, at the moment. Maybe it will be, but not quite yet. Reimbursement. We have two specific things on reimbursement in the U.S. We have first, the end of the reimbursement of our TruGraf test, which happened last year, but is still impacting two or three quarters this year. Then we have a small activity we haven't talked a lot about. It's about EUR 100 million, but it is called Donor Products Testing, where we test organs or we test cells that will be used, that will be implanted, transplanted. The requirement for testing, it's not only reimbursement, it's mostly the policy of how often and what tests have to be done for organ transplant, and that has changed recently. That is starting to affect from Q1 of this year. Those are the two things we were referring to. That's very helpful. Thank you. Can I perhaps just ask a follow-up, related to the first question around your comment around margins, expecting significant progress. Obviously, the investments you've made have been one of the supports to margins, and most evident in the U.S. Does that comment that you made around margin confidence apply both to the U.S. and to Europe as well, for this year? Yes. Real margin. Margins will improve just by construction. There are many things we've spent a lot of money on, reorganization and so on, that are coming to an end or have ended. Once we have the right site footprint, we don't have to have the shutdown. Also, the impact on the top line of shutdowns. When you shut down sites and consolidate, you always lose a bit of revenue, so that's not good for the top line. Of course, once you have finished the consolidation and the new IT systems are bedded down and everything, you gain efficiency, so you need fewer people. In Europe, we have a huge catch up because there was much more duplication. There is still much more duplication in our network in Europe than North America, and diversity of IT systems. Because each country had deployed older versions of our system, which was configured differently in each country, the cost of maintaining that is much higher. If I look at our IT costs in Europe, there are 5% of revenues in Europe versus 3% in the U.S. Already there, you've got a difference. That should normalize once we have standardized everything. That gives some idea of the impact and why, irrespective of revenue growth, it's not only volume drop-through, we believe we will improve profitability. Great. That's very helpful. Thank you. Thank you. Our next question is coming from Delphine Le Louët with Bernstein. Your line is live. Thank you. Hello, everybody. Hi, Gilles. Just to follow up on this margin story or the way you look at the margin and specifically into minding the gap in between the U.S. and the European margin. How should we think about the size of the gap in the next five years? This is the first one. The second one is really back to HRIS, to what is happening exactly on the margin into Q1 when you say, we have these structural and mechanical gains due to the hub-and-spoke. Can you be more specific and possibly separate what you see coming out from the mix effects and what you see, let's say, more broadly coming from the COGS? Finally, the question deals with the CDMO Canadian business that you bought and effectively you had at the time of the buying some contract for a certain duration. Can we size actually what is the CDMO precisely in terms of revenue? Because we have the catch-up into the biomanufacturing happening right now, why you're not more, in a way, active or being more successful in bringing new contract to the table to make this facility running at full capacity? Thank you. Yeah. The size of the gap between the U.S. and Europe is big in profitability. I don't think we'll ever fully catch up, although there were activities and areas in Europe where we have higher margin than in North America in the same business. It's not impossible. It just needs the proper focusing on the sites and also finalization of all those very disruptive new digitalization programs. I think the gap, can we halve the gap? I don't know. We haven't made any objective beyond 2027, so I can't be specific about that. Again, in Q1, I cannot tell you more than what's in the press release. Otherwise, we'll have to do a new press release. I'm sorry. We are confident that we'll improve margins in a way to achieve our objectives for this year and next year. That has gone well in that direction in the first quarter of this year. On CDMO. Yeah. You're right, significantly. How should we think about that? Should we think as a sort of a doubling of what you see into the organic growth or what the range? I presume you can give us a flavor. I'm not sure I understand your question, but I cannot give you a number, because otherwise I would have to issue a press release. I cannot give much more than saying that we are completely confident on achieving our margin progression for this year and next year, and the evolution in Q1 fully underlines that and makes us also even more confident about it. That's all I can say, I'm afraid. Otherwise, we think about sometime publishing a full financial report also for Q1 and Q3. That would have some benefit, because indeed, discussing just the top line growth is not much information for you guys to do your planning. We're not there yet. We haven't decided to do that. Maybe we should at some point. It is a valid question, Delphine, and I understand. Just what we can give short of publishing a full P&L is frustrating. Yes, whether it's the COGS or the top line. COGS, improvement of COGS is linked to our purchasing effect. The way we define it is mostly external cost. If you include labor, lab labor, of course, that comes from productivity, and we have gains there. Also we have a program to use our overheads better. That's going to be a multi-year program. We think we can go beyond what we plan in terms of margin for but we first need to deliver that before we talk about what is possible after that. To your second question on CDMO, that's globally about EUR 100 million business. In Canada, we bought a small business, but we mostly expanded it. We've built a big site now, and every time we expand, it takes two years to fill. Not to fill, but to qualify, to build the room, to build the equipment, to qualify the equipment so that it can be filled. It's very lumpy. We will do an investors day, I think, this year in Toronto, so you can see the facility, and we can talk more about that. Our CDMO was affected in Europe this quarter because we do more biologics in Europe, or in Canada also, but not only. They had some contract that just ended. There was one client that had a clinical trial that didn't go well, so that stopped. Overall, this CDMO in Europe is doing a lot of early stage and has been more affected by the funding issues of biotech. Of course, we get the impact a few quarters after the clients run out of money because the projects continue. They don't end abruptly. That's what I can say with CDMO. Our positioning in Europe is good. It's mostly biologics, so when that picks up, we should be able to get good new contracts. Thanks a lot. Thank you. Once again, ladies and gentlemen, if you do have any questions or comments, please press star one on your telephone keypad. Thank you. Our next question is coming from Suhasini Varanasi with Goldman Sachs. Your line is live. Hi. Good afternoon. Thank you for taking my questions. Just three for me, please. Just to clarify, it's a weaker start to the year, but you've maintained your guide for mid-single-digit organic growth full year. Can you maybe clarify how trends were in March and maybe early April? Did it return to more than 5% levels? Second question. We've obviously seen some news flow on AI partnerships by big pharma players, and there's some concern in the market that it could lead to more insourcing of biopharma R&D. Can you discuss the risks to Eurofins if this trend were to happen? The last one is on contract exits, specifically in clinical SYNLAB. How much will it impact Q1 growth, please? Thank you. Okay. I think you were cut off, but I think the first question regarded the exit rate for growth, and I alluded to that earlier, saying we had a quite strong March, and even correcting for the extra working day, we're mid-single digits. That's one point. AI partnerships, that's more for discovery. We don't do a lot of discovery. We have an AI company also that works with clients to use a lot of data points we have for discovery to help them. Actually, if there is more discovery, there will be more work flowing through our labs because you cannot replace what we do with AI for the BioPharma Product Testing. This is mandatory. This is testing with machine, and that is part of the, what is it called, the filing registration. How the product will be tested is part of the registration of the product. I don't really see what AI will impact for the type of business that we do, which requires brick and mortar and labs and touching the sample. If there are more products developed, the biopharma will not in-source BioPharma Product Testing because they bring more molecules in the clinic. They decided to outsource it long ago, and I don't see why that would change because of AI. SYNLAB, I think, over a number of months, quarters, we plan to shed EUR 20 million or EUR 25 million of revenues. That was what we announced when we bought it. That has started, of course, immediately when we bought it. In the first quarter, what the impact is, I can't tell, but it's significant. We're talking this year, probably still EUR 10 million that will be shaved off the activity of that business. Now, of course, we also increase prices. We do offset because we don't lose all the contracts. Sometimes we manage to conclude them at a higher price that provides the right profitability. It's a complex multiple pieces moving. Thank you very much. Thank you. This is all the questions we have for today's question and answer session. We would like to turn the conference back to Dr. Gilles Martin for closing remarks. Thank you very much. Well, thank you very much to all of you for your questions. As I mentioned, it's a bit frustrating to just talk about revenues, especially when we've had a soft quarter with a big impact on weather. I think the outlook has not changed. We're confident that we should be doing mid-single digits growth this year, improve our margins, continue to build a strong competitive advantage, have a more efficient, more digital, more differentiated business, which our clients love. And also, we are fortunate to be in a resilient industry. We do things that are not directly tied to energy. Of course, inflation can be a few percent. I had a question, how much is energy? I think maybe energy is 3%-4% of our cost between transportation and heating and so on. It's not an enormous impact. It is an impact, but not super enormous. In good or bad times, food has to be safe and tested. The air we breathe, the water we drink, has to be safe. There is more biopharmaceutical research. The development in these areas are super exciting and more products will be developed, and we provide some of the picks and shovels to get product registered. We're feeling good about all our activities. We think they are resilient, even in very unpredictable times. We are getting close to having built a very efficient and very profitable lab network with very high market shares and strong differentiation. Thank you for your support, and we'll talk more in three months with profitability numbers that I hope you will all like. Thank you very much. Thank you. Ladies and gentlemen, the call is now concluded, and you may disconnect your telephones at this time. Thank you for joining, and have a pleasant day.